Veradigm FollowMyHealth Named Most Improved Software Product by KLAS
Veradigm Inc. (NASDAQ: MDRX) announces that its patient engagement platform, Veradigm FollowMyHealth, has been recognized by KLAS as the Most Improved Software Product in the 2023 Best in KLAS report.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Veradigm FollowMyHealth customer satisfaction has improved more than any other software solution over the past year, strengthening patient care and experience
With a mobile-first approach, Veradigm FollowMyHealth helps meet patients on their terms and delivers patient accessibility with an integrated approach to patient engagement. A complete patient care experience promotes a collaborative environment with ease of access and convenience. Veradigm FollowMyHealth offers a real-time gateway across demographic groups, while producing an immediate, proven value for independent practices and health systems. With growing healthcare utilization, Veradigm FollowMyHealth brings timing and technology together, helping improve both the patient and healthcare provider’s experiences.
“As a patient engagement leader for over ten years, Veradigm FollowMyHealth is constantly working to improve our solutions and delight both our clients and the patients that depend on us,” said
About Veradigm®
Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully. For more information on Veradigm, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005325/en/
Investors:
312-506-1237
jenny.gelinas@veradigm.com
Media:
312-447-2466
concetta.rasiarmos@veradigm.com
Source: